[Effects of PCMV4-hTGF beta 1 as nucleic acid vaccine on II* burn wound healing and postburn scarring in rats].
OBJECTIVE
To investigate the gene expression of PCMV4-hTGF beta 1 as nucleic acid vaccine regulation and the effects on burn wound healing and scarring in rats and study the feasibility of gene therapy in burns.


METHODS
Sixty wistar rats were divided into three groups: 1. burn + nucleic acid vaccine; 2. nucleic acid vaccine only(control); 3. burn only(control). ELISA was used to determine the dynamic changes in anti-TGF beta 1 neutralizing antibody in serum; determination of the quantities of DNA retained in muscles by Southern blot and in situ hybridization; observation of the ratio in collagen I/III during the wound healing by special stain method.


RESULTS
The level of anti-TGF beta 1 antibody in serum reached the peak at the third week after naked DNA was injected, and a slight drop in the 4th week. TGF beta 1 plasmid DNA could be detected 5 minute after injection, and lasted 3 hours. In situ hybridization showed a positive staining in muscle fibers 5 days after injection. During the day 0-day 9, the wound healing speed in vaccine group was faster than control, and after day 10, no significant difference was found between groups, but the ratio of collagen I/III was reduced remarkably in vaccine group.


CONCLUSIONS
Injection of PCMV4-hTGF beta 1 in rats can really cause general immune response reaction. It was showed that PCMV4-hTGF beta 1 was similar to TGF beta 1, and it had the effect of stimulating of epidermic cells to accelerate wound healing at early stage, and at later stage, it was similar to anti-TGF beta 1 neutralizing antibody, having the effect of inhibiting hyperplasia of scar. So it is confirmed that PCMV4-hTGF beta 1 as nucleic acid vaccine has the effect of promoting healing of burn wound and controlling the formation of scar.
Jia
C
C
Department of Burn Surgery, Xijing Hospital, Xi'an 710032.
Chen
B
B
Wang
D
D
D000818:Animals; D002056:Burns / Q000628:therapy*; D017439:Cicatrix, Hypertrophic / Q000517:prevention & control*; D003587:Cytomegalovirus / Q000235:genetics; D008297:Male; D010957:Plasmids; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000276:immunology / Q000627:therapeutic use; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000627:therapeutic use*; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use*; D014945:Wound Healing / Q000187:drug effects*
D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; D019444:Vaccines, DNA